New Osteoporosis Guidelines; Pediatric Growth Hormone OK’d; Defining T2D Remission

The North American Menopause Society released a new position statement on the screening, prevention, diagnosis, and management of osteoporosis in postmenopausal women. (Menopause)

The FDA approved lonapegsomatropin-tcgd (Skytrofa) for the treatment of pediatric patients who weigh at least 25.4 lb (11.5 kg) and have growth failure due to inadequate secretion of endogenous growth hormone, Ascendis Pharma announced. The once-weekly injection is the first approved treatment that delivers somatropin by sustained release over the course of the week.

Due to contracts with payers and type of insurance, Lantus might still come out as the cheaper option for some patients with diabetes compared with Semglee insulin glargine — just approved as the first interchangeable biosimilar insulin — despite the fact that Semglee is about 64% cheaper than Lantus based on its wholesale cost in the U.S. (GlobalData)

The Endocrine Self-Assessment Program In-Training Examination is highly predictive of pass/fail outcomes on the American Board of Internal Medicine-Endocrinology, Diabetes, and Metabolism Certification Examination, a new study found. (Journal of the Endocrine Society)

Building on a recent report, the FDA released the latest slew of results quantifying per- and polyfluoroalkyl substances (PFAS) in nationally distributed processed foods. All in all, 164 of the 167 foods tested had no detectable levels of PFAS and the only foods to show contamination were fish sticks, canned tuna, and protein powder.

The Endocrine Society announced that it established a new executive-level role focused on membership and diversity, which will first be filled by Rodneikka Scott, MSc, CAE.

Remission of type 2 diabetes should be defined as an HbA1c below 6.5% (48 mmol/mol) measured at least 3 months after cessation of glucose-lowering pharmacotherapy, according to a group of international researchers in a new consensus report published in the Journal of Clinical Endocrinology & Metabolism.

During the first COVID-19 wave in England, hospital admissions for diabetic ketoacidosis dropped for patients with type 1 diabetes, but increased for those with type 2 diabetes and those newly diagnosed with diabetes. (The Lancet Diabetes & Endocrinology)

The FDA approved the first and only treatment of pruritus associated with chronic kidney disease in adults undergoing hemodialysis: difelikefalin (Korsuva), Cara Therapeutics and Vifor Pharma announced.